Drug Trial Radar · NCT04974749
A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease
Last checked: Nov 20, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
May 1, 2022
Primary completion
Jan 3, 2024
Study completion Jan 3, 2024
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jul 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 7 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of the study is to assess the safety of REPLAGAL. Study participants will receive REPLAGAL as an intravenous infusion every other week for 52 weeks. Participants will visit their study clinic many times throughout the study.
Conditions
- Fabry Disease
Interventions
REPLAGALBiological
REPLAGAL IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs)Time frame: From start of study drug administration up to 14 days after end of treatment (EOT) [up to Week 54]
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China
Xiangya Hospital, Central South University
Changsha, China
West China Hospital, Sichuan University
Chengdu, China
The Children's Hospital of Zhejiang University School of Medicine
Hangzhou, China
Shandong Provincial Hospital
Jinan, China
Ruijin Hospital, Shanghai Jiaotong Uni. School of Med.
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.